Trial · NCT02597855
Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
NCT02597855, Unknown, Yeungnam University College of Medicine; results first posted 2016-06-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy. Trials, record NCT02597855. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02597855
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
- NCT number
- NCT02597855
- Status
- Unknown
- Enrollment
- 29 participants, actual
- Lead sponsor
- Yeungnam University College of Medicine
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- Aflibercept, Indocyanine green angiography (intraveonus indocyanine green dye)
- First posted
- 2015-11-05
- Last updated
- 2016-08-18
- Results first posted
- 2016-06-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Regression Rate of Polyp on Indocyanine Green Angiography | 3 months | Indocyanine green angiography performed initially and at 3 months were used to determine the polyp regression. The definition of complete polyp regression is that the polyps at initial visit disappeared at 3 months on indocyanine green angiography. The partial regression means the polyps remain, but the size decreased \>30%. |
| Secondary | Best Corrected Visual Acuity | baseline, 3 months, and 6 monthsc | Best corrected visual acuity assessed at baseline, 3 months, and 6 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Regression Rate of Polyp on Indocyanine Green Angiography | 3 months | Participants who were finished 6 months follow up period. | participants | NUMBER |
| SECONDARY | Best Corrected Visual Acuity | baseline, 3 months, and 6 monthsc | Participants who were finished 6 months follow up period. | LogMAR | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 1 Polypoidal Choroidal Vasculopathy | Complete polyp regression | 13 | participants | |
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 2 Polypoidal Choroidal Vasculopathy | Complete polyp regression | 4 | participants | |
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 1 Polypoidal Choroidal Vasculopathy | Partial polyp regression | 3 | participants | |
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 2 Polypoidal Choroidal Vasculopathy | Partial polyp regression | 7 | participants | |
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 1 Polypoidal Choroidal Vasculopathy | No regression | 0 | participants | |
| Regression Rate of Polyp on Indocyanine Green Angiography | Type 2 Polypoidal Choroidal Vasculopathy | No regression | 2 | participants | |
| Best Corrected Visual Acuity | Type 1 Polypoidal Choroidal Vasculopathy | 3 months | 0.39 | Standard Deviation 0.36 | LogMAR |
| Best Corrected Visual Acuity | Type 2 Polypoidal Choroidal Vasculopathy | 3 months | 0.54 | Standard Deviation 0.34 | LogMAR |
| Best Corrected Visual Acuity | Type 1 Polypoidal Choroidal Vasculopathy | 6 months | 0.44 | Standard Deviation 0.26 | LogMAR |
| Best Corrected Visual Acuity | Type 2 Polypoidal Choroidal Vasculopathy | 6 months | 0.49 | Standard Deviation 0.36 | LogMAR |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Type 1 Polypoidal Choroidal Vasculopathy | 18 | |
| Overall Study | STARTED | Type 2 Polypoidal Choroidal Vasculopathy | 14 | |
| Overall Study | COMPLETED | Type 1 Polypoidal Choroidal Vasculopathy | 16 | |
| Overall Study | COMPLETED | Type 2 Polypoidal Choroidal Vasculopathy | 13 | |
| Overall Study | NOT COMPLETED | Type 1 Polypoidal Choroidal Vasculopathy | 2 | |
| Overall Study | NOT COMPLETED | Type 2 Polypoidal Choroidal Vasculopathy | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Type 1 Polypoidal Choroidal Vasculopathy | ||
| Total, all-cause mortality | Type 2 Polypoidal Choroidal Vasculopathy | ||
| Total, other adverse events | Type 1 Polypoidal Choroidal Vasculopathy | 0 | 18 |
| Total, other adverse events | Type 2 Polypoidal Choroidal Vasculopathy | 0 | 14 |
| Total, serious adverse events | Type 1 Polypoidal Choroidal Vasculopathy | 0 | 18 |
| Total, serious adverse events | Type 2 Polypoidal Choroidal Vasculopathy | 0 | 14 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27597740 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Type 1 Polypoidal Choroidal Vasculopathy vs Type 2 Polypoidal Choroidal Vasculopathy: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02597855
GET https://conductscience.org/api/trials/v1/NCT02597855/registered